Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand

Cell Death and Disease

Volumn 7, Issue , 2016, Pages e2058-

  Baig, S ^a,b   Seevasant, I ^a   Mohamad, J ^b   Mukheem, A ^a   Huri, H Z ^a,c   Kamarul, T ^a,c  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BH3 PROTEIN; DEATH RECEPTOR; HISTONE DEACETYLASE INHIBITOR; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; PROTEIN BCL 2; SMALL MOLECULE TRANSPORT AGENT; TUMOR NECROSIS FACTOR;

APOPTOSIS; BIOMIMETICS; CANCER RESEARCH; CARCINOGENESIS; CELL DEATH; GENE EXPRESSION REGULATION; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; GENETICS; PATHOLOGY; THERAPEUTIC RESEARCH;

APOPTOSIS; HUMANS; NEOPLASMS; THERAPEUTIC HUMAN EXPERIMENTATION;

EID: 84955078721     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.275     Document Type: Review

References (179)

1. Walsh CM. Grand challenges in cell death and survival: apoptosis vs. necroptosis. Front Cell Dev Biol 2014; 2: 3.
2. Adams J, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-1337.
3. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49-63.
4. Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007; 19: 488-496.
5. Claveria C, Giovinazzo G, Sierra R, Torres M. Myc-driven endogenous cell competition in the early mammalian embryo. Nature 2013; 500: 39-44.
6. Riether C, Schurch CM, Ochsenbein AF. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ 2014; 22: 187-198.
7. Vaux DL, Haecker G, Strasser A. An evolutionary perspective on apoptosis. Cell 1994; 76: 777-779.
8. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005; 5: 189-200.
9. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 2010; 1805: 53-71.
10. Vaux DL. Cell Death and Cancer. Cell Death 2014: 121-134.
11. Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 2014; 21: 39-49.
12. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009; 361: 1570-1583.
13. Golstein P. Cell death in us and others. Science (New York, NY) 1998; 281: 1283.
14. Yuan J, Kroemer G. Alternative cell death mechanisms in development and beyond. Genes Dev 2010; 24: 2592-2602.
15. Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev 2003; 17: 2481-2495.
16. Shi Y. Mechanical aspects of apoptosome assembly. Curr Opin Cell Biol 2006; 18: 677-684.
17. Zamzami N, Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2001; 2: 67-71.
18. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science (New York, NY) 1997; 275: 1132-1136.
19. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1 a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405-413.
20. Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int 2014; 2014: 150845.
21. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 1998; 60: 619-642.
22. Reed JC, Kromer G. Mitochondrial control of cell death. Nat Med 2000; 6: 513-519.
23. Lavrik IN, Eils R, Fricker N, Pforr C, Krammer PH. Understanding apoptosis by systems biology approaches. Mol Biosyst 2009; 5: 1105-1111.
24. Schleich K, Lavrik IN. Mathematical modeling of apoptosis. Cell Commun Signal 2013; 11: 44.
25. Lavrik IN. Systems biology of apoptosis signaling networks. Curr Opin Biotechnol 2010; 21: 551-555.
26. Schleich K, Krammer PH, Lavrik IN. The chains of death: a new view on caspase-8 activation at the DISC. Cell Cycle (Georgetown, Tex) 2013; 12: 193-194.
27. Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 2004; 64: 9105-9114.
28. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4: 333-339.
29. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430.
30. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8: 782-798.
31. Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 2009; 10: 348-355.
32. Kischkel F, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer P et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14: 5579.
33. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol 2007; 7: 532-542.
34. Lavrik I. Systems biology of death receptor networks: live and let die. Cell Death Dis 2013; 5: e1259.
35. Liu JJ, Lin M, Yu JY, Liu B, Bao JK. Targeting apoptotic and autophagic pathways for cancer therapeutics. Cancer Lett 2011; 300: 105-114.
36. Ubah OC, Wallace HM. Cancer therapy: targeting mitochondria and other sub-cellular organelles. Curr Pharmaceut Des 2014; 20: 201-222.
37. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-348.
38. Liu J-j Lin M, Yu J-y, Liu B, Bao J-k. Targeting apoptotic and autophagic pathways for cancer therapeutics. Cancer Lett 2011; 300: 105-114.
39. Gautschi O, Tschopp S, Olie RA, Leech SH, Simões-Wüst AP, Ziegler A et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 2001; 93: 463-471.
40. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126-1132.
41. Papadopoulos K. Targeting the Bcl-2 family in cancer therapy. Semin Oncol (Elsevier) 2006; 33: 449-456.
42. Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets 2013; 17: 61-75.
43. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-219.
44. Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 2005; 17: 617-625.
45. Giam M, Huang D, Bouillet P. BH3-only proteins and their roles in programmed cell death. Oncogene 2008; 27: S128-S136.
46. Labi V, Erlacher M, Kiessling S, Villunger A. BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Differ 2006; 13: 1325-1338.
47. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183-192.
48. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525-535.
49. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP et al. bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88.
50. Strasser A, Harris AW, Cory S. bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 1991; 67: 889-899.
51. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t (14; 18) chromosome translocation. Science (New York, NY) 1984; 226: 1097-1099.
52. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-1305.
53. Dias N, Stein C. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002; 1: 347-355.
54. Bacon TA, Morvan F, Rayner B, Imbach J-L, Wickstrom E. α-Oligodeoxynucleotide stability in serum, subcellular extracts and culture media. J Biochem Biophys Methods 1988; 16: 311-318.
55. Wickstrom E. Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods 1986; 13: 97-102.
56. Akhtar S, Kole R, Juliano R. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci 1991; 49: 1793-1801.
57. Paula Simões-Wüst A, Hopkins-Donaldson S, Sigrist B, Belyanskaya L, Stahel RA, Zangemeister-Wittke U. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis. Oligonucleotides 2004; 14: 199-209.
58. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
59. Kamal A, Faazil S, Malik M S. Apoptosis-inducing agents: a patent review (2010-2013). Expert Opin Ther Patents 2014; 24: 339-354.
60. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008; 26: 870-876.
61. Marcucci G, Moser B, Blum W, Stock W, Wetzler M, Kolitz J. A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. J Clin Oncol 2007; 25: 7012.
62. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738-4745.
63. Ozvaran MK, Cao XX, Miller SD, Monia BA, Hong WK, Smythe WR. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma. Mol Cancer Ther 2004; 3: 545-550.
64. Johnston JB, Paul JT, Neufeld NJ, Haney N, Kropp DM, Hu X et al. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leuk Lymphoma 2004; 45: 2017-2027.
65. Allal AS, Waelchli L, Bründler M-A. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma. Clin Cancer Res 2003; 9: 6489-6496.
66. Herbst RS, Frankel SR. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 2004; 10: 4245s-4248s.
67. Glozak M, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26: 5420-5432.
68. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C. Histone deacetylase inhibitors and genomic instability. Cancer Lett 2009; 274: 169-176.
69. Hrabeta J, Stiborova M, Adam V, Kizek R, Eckschlager T. Histone deacetylase inhibitors in cancer therapy. A review. Biomed Pap 2014; 158: 161-169.
70. Becher I, Dittmann A, Savitski M M, Hopf C, Drewes G, Bantscheff M. Chemoproteomics reveals time-dependent binding of histone deacetylase inhibitors to endogenous repressor complexes. ACS Chem Biol 2014; 9: 1736-1746.
71. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124: 30-39.
72. Bolden J E, Peart M J, Johnstone R W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784.
73. Ellis L, Bots M, Lindemann R K, Bolden J E, Newbold A, Cluse L A et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 2009; 114: 380-393.
74. Momparler RL, Côté S, Momparler LF, Idaghdour Y. Epigenetic therapy of acute myeloid leukemia using 5-aza-2′-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation. Clin Epigenet 2015; 6: 19.
75. Li W, Gong X, Sun M, Zhao X, Gong B, Wei H et al. High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis. PLoS ONE 2014; 9: e110153.
76. Grishina O, Schmoor C, Döhner K, Hackanson B, Lubrich B, May AM. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy. BMC Cancer 2015; 15: 430.
77. Cea M, Cagnetta A, Gobbi M, Patrone F, Richardson PG, Hideshima T et al. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharmaceut Des 2013; 19: 734-744.
78. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410-5417.
79. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Invest Drugs 2010; 19: 1049-1066.
80. Bai L, Wang S. Targeting apoptosis pathways for new cancer therapeutics. Annu Rev Med 2014; 65: 139-155.
81. Kögel D. Exploiting BH3 Mimetics for Cancer Therapy. Mitochondria: The Anti-cancer Target for the Third Millennium. Springer 2014; 39-58.
82. Lheureux S, N'Diaye M, Blanc-Fournier C, Dugué AE, Clarisse B, Dutoit S et al. Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma. Int J Cancer 2015; 13: E340-E350.
83. Llambi F, Moldoveanu T, Tait SW, Bouchier-Hayes L, Temirov J, McCormick LL et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 2011; 44: 517-531.
84. Mérino D, Giam M, Hughes PD, Siggs OM, Heger K, O'Reilly LA et al. The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol 2009;186: 355-362.
85. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911.
86. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
87. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science (New York, NY) 2007; 315: 856-859.
88. Certo M, Moore VDG, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
89. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG et al. BAX activation is initiated at a novel interaction site. Nature 2008; 455: 1076-1081.
90. Kim H, Rafiuddin-Shah M, Tu H-C, Jeffers JR, Zambetti GP, JJ-D Hsieh et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006; 8: 1348-1358.
91. Lee M-S, Ha J-H, Yoon HS, Lee C-K, Chi S-W. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins. Biochem Biophys Res Commun 2014; 445: 120-125.
92. Lindqvist LM, Heinlein M, Huang DC, Vaux DL. Prosurvival Bcl-2 family members affect autophagy only indirectly by inhibiting Bax and Bak. Proc Natl Acad Sci 2014; 111: 8512-7.
93. Liu Q, Chi X, Leber B, Andrews DW. Bcl-2 family and their therapeutic potential. In:WU H (ed) Cell Death. Springer: New York, NY, USA, 2014, pp 61-96.
94. Fairbrother WJ, Ashkenazi A. Designer proteins to trigger cell death. Cell 2014; 157: 1506-1508.
95. Moldoveanu T, Follis AV, Kriwacki RW, Green DR. Many players in BCL-2 family affairs. Trends Biochem Sci 2014; 39: 101-111.
96. Polier G, Giaisi M, Köhler R, Müller W W, Lutz C, Buss E C et al. Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263. Int J Cancer 2015; 136: 688-698.
97. Renault TT, Elkholi R, Bharti A, Chipuk JE. BH3 mimetics demonstrate differential activities dependent upon the functional repertoire of pro-and anti-apoptotic BCL-2 family proteins. J Biol Chem 2014; M114: 569632.
98. Hassig C A, Zeng F Y, Kung P, Kiankarimi M, Kim S, Diaz P W et al. Ultra-high-throughput screening of natural product extracts to identify proapoptotic inhibitors of Bcl-2 family proteins. J Biomol Screen 2014; 19: 1201-1211.
99. Ryu Y, Hall CP, Reynolds CP, Kang MH. Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines. Exp Biol Med 2014; 239: 1390-1402.
100. Wroblewski D, Mijatov B, Mohana-Kumaran N, Lai F, Gallagher SJ, Haass NK et al. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis 2013; 34: 237-247.
101. LaCasse E, Mahoney D, Cheung H, Plenchette S, Baird S, Korneluk R. IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252-6275.
102. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104: 263-269.
103. Rustum YM. Thymidylate synthase: a critical target in cancer therapy? Front Biosci 2004; 9: 2467-2473.
104. Schultz R, Patel V, Worzalla J, Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1998; 19: 437-443.
105. Khan KH, Blanco-Codesido M, Molife L. Cancer therapeutics: targeting the apoptotic pathway. Crit Rev Oncol/Hematol 2014; 90: 200-219.
106. Deveraux QL, Takahashi R, Salvesen GS, Reed JC, X-linked IAP. is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300-304.
107. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998; 17: 2215-2223.
108. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252-6275.
109. Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ 2014; 21: 1350-1364.
110. Ramp U, Krieg T, Caliskan E, Mahotka C, Ebert T, Willers R et al. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol 2004; 35: 1022-1028.
111. Ferreira CG, van der Valk P, Span SW, Jonker JM, Postmus PE, Kruyt FA et al. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann Oncol 2001a; 12: 799-805.
112. Ferreira CG, van der Valk P, Span SW, Ludwig I, Smit EF, Kruyt FA. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res 2001b; 7: 2468-2474.
113. Liu S, Tsang BK, Cheung AN, Xue WC, Cheng DK, Ng TY. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer 2001; 37: 1104-1110.
114. Mao HL, Liu PS, Zheng JF, Zhang PH, Zhou LG, Xin G et al. Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro. Pharmacol Res 2007; 56: 483-492.
115. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8: 393-406.
116. Mannhold R, Fulda S, Carosati E. IAP antagonists: promising candidates for cancer therapy. Drug Discov Today 2010; 15: 210-219.
117. Lavrik IN. Systems biology of death receptor networks: live and let die. Cell Death Dis 2014; 5: e1259.
118. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
119. LeBlanc H, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.
120. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821.
121. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954-960.
122. Dimberg L, Anderson C, Camidge R, Behbakht K, Thorburn A, Ford H. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2012; 32: 1341-1350.
123. Nebbioso A, Carafa V, Benedetti R, Altucci L. Trials with 'epigenetic'drugs: an update. Mol Oncol 2012; 6: 657-682.
124. Qiu T, Zhou L, Zhu W, Wang T, Wang J, Shu Y et al. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncol 2013; 9: 255-269.
125. Falkenberg K J, Johnstone R W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Disc 2014; 13: 673-691.
126. Badros A, Burger A M, Philip S, Niesvizky R, Kolla S S, Goloubeva O et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009; 15: 5250-5257.
127. Weber D M, Graef T, Hussein M, Sobecks R M, Schiller G J, Lupinacci L et al. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012; 12: 319-324.
128. Mottamal M, Zheng S, Huang T L, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 2015; 20: 3898-3941.
129. Brinkmann K, Kashkar H. Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? Cell Death Dis 2014; 5: e1098.
130. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 2008; 143: 355-360.
131. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 3920-3927.
132. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11: 3854-3861.
133. Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y et al. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004; 15: 1274-1283.
134. Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 2005; 23: 3404-3411.
135. Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004; 22: 1110-1117.
136. Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ et al. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma 2009; 50: 559-565.
137. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009; 113: 299-305.
138. Moore J, Seiter K, Kolitz J, Stock W, Giles F, Kalaycio M et al. A phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res 2006; 30: 777-783.
139. Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 2011; 74: 481-485.
140. Parikh SA, Kantarjian H, Schimmer A, Walsh W, Asatiani E, El-Shami K et al. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma myeloma Leuk 2010; 10: 285-289.
141. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009; 15: 3172-3176.
142. Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol 2012; 23: 1803-1808.
143. Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat 2001; 66: 239-248.
144. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. The Lancet Oncol 2010; 11: 1149-1159.
145. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488-496.
146. Dai Y, Liu M, Tang W, DeSano J, Burstein E, Davis M et al. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin Cancer Res 2008; 14: 7701-7710.
147. Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 2010; 70: 2852-2861.
148. Dai Y, Liu M, Tang W, Li Y, Lian J, Lawrence TS et al. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. BMC Cancer 2009; 9: 392.
149. Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J et al. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol 2009; 27: 1660-1666.
150. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008; 26: 5198-5203.
151. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 3872-3880.
152. Rödel F, Frey B, Leitmann W, Capalbo G, Weiss C, Rödel C. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 2008; 71: 247-255.
153. Yee L, Burris H, Kozloff M, Wainberg Z, Pao M, Skettino S. Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): preliminary results. J Clin Oncol 2009; 27: 4129.
154. Soria J-C, Márk Z, Zatloukal P, Szima B, Albert I, Juhász E et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 2011; 37: 623.
155. Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008; 14: 3450-3455.
156. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008; 61: 82-90.
157. Trarbach T, Moehler M, Heinemann V, Köhne C, Przyborek M, Schulz C et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 2010; 102: 506-512.
158. Saleh M, Percent I, Wood T, Posey J, Shah J, Carlisle R et al. A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas. J Clin Oncol 2008; 26: 3537.
159. Camidge DR. Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. Expert Opin Biol Ther 2008: 1167-1176.
160. Wakelee H, Patnaik A, Sikic B, Mita M, Fox N, Miceli R et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2010; 21: 376-381.
161. Pacey S, Plummer R, Attard G, Bale C, Calvert A, Blagden S et al. Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies. J Clin Oncol 2005; 23: 3055.
162. LoRusso P, Hong D, Heath E, Kurzrock R, Wang D, Hsu M et al. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. J Clin Oncol 2007; 25: 3534.
163. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu C-P, Goyal L et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 2010; 16: 5883-5891.
164. Banerji U, van Doorn L, Papadatos-Pastos D, Kristeleit R, Debnam P, Tall M et al. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res 2012; 18: 2687-2694.
165. Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM et al. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 2014: 1-4.
166. Zorzi AP, Bernstein M, Samson Y, Wall DA, Desai S, Nicksy D et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. Pediatr Blood Cancer 2013; 60: 1868-1874.
167. Gray JE, Haura E, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenck M et al. A phase I, pharmacokinetic, and pharmacodynamic study of Panobinostat, an HDAC inhibitor, combined with Erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res 2014; 20: 1644-1655.
168. Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J et al. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 2011; 106: 77-84.
169. Dong M, Ning ZQ, Xing PY, Xu JL, Cao HX, Dou GF et al. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol 2012; 69: 1413-1422.
170. Galli M, Salmoiraghi S, Golay J, Gozzini A, Crippa C, Pescosta N et al. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 2010; 89: 185-190.
171. Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A et al. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res 2013; 19: 4262-4272.
172. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong T-C, Prince HM et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012; 30: 2197-2203.
173. Fukutomi A, Hatake K, Matsui K, Sakajiri S, Hirashima T, Tanii H et al. A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs 2012; 30: 1096-1106.
174. Berenson JR, Hilger JD, Yellin O, Boccia RV, Matous J, Dressler K et al. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Ann Hematol 2014; 93: 89-98.
175. Bauer S, Hilger RA, Muhlenberg T, Grabellus F, Nagarajah J, Hoiczyk M et al. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer 2014; 110: 1155-1162.
176. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008; 112: 3807-3817.
177. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99: 1885-1893.
178. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1 a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 1997; 89: 630-643.
179. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803.